The Society for Clinical Research Sites (SCRS), the global trade organization fully dedicated to representing the interests of clinical research sites, today announced an expanded partnership with the eClinical division of Merge Healthcare, an IBM company. Merge is a leading provider of software solutions for the clinical research industry.
“We are pleased to have Merge’s support for a number of important initiatives and member programs,” said Christine Pierre, president of SCRS. “This level of partnership is symbolic of Merge’s deep commitment to creating a sustainable future for clinical research sites globally.”
As a Site Engagement Partner, Merge will continue to participate on the SCRS Global Impact Board at an executive level, and work closely with SCRS’ Leadership Council to determine strategic initiatives for SCRS.
About SCRS
SCRS is a global trade organization founded in 2012 which represents over 2,600 research sites in 42 countries. SCRS’ mission is to unify the voice of the global clinical research site community for greater site sustainability. SCRS has become an active partner in industry-wide initiatives and dialogues focused on improving the clinical research enterprise. Sites and the companies that sponsor or support the work conducted at clinical research sites will benefit from membership and partnership. Visit MySCRS.org.
About Merge eClinical
The eClinical division of Merge Healthcare, an IBM Company, is a leading provider of cloud-based software solutions for the clinical research industry. Our flagship products include eClinicalOS (eCOS) and CTMS for Investigators (CTMSi). eCOS is a single, scalable platform that allows Sponsors, CROs, and academic researchers to capture and manage clinical data with ease. CTMSi is a comprehensive clinical trial management system that helps site professionals organize and centralize the study management process. Get more information at www.eclinicalos.com.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Gilead Shares Final Data from Phase III MYR301 Trial of Bulevirtide in Chronic Hepatitis Delta Virus
May 7th 2025Long-term results from the study show 90% of patients with chronic HDV who achieved undetectable HDV RNA at 96 weeks of treatment remained undetectable for nearly 2 years post-treatment.